SRI International will conduct preclinical studies of a Telik drug candidate for the treatment of multiple sclerosis and other autoimmune and inflammatory diseases under an exclusive license agreement.
The licensing agreement involves the study of C243, a compound that prevents leukocyte infiltration, which is strongly linked to tissue injury in chronic autoimmune and inflammatory diseases.
Under the terms of the agreement, SRI will fund and conduct preclinical and toxicology studies directed at supporting an IND application filing for C243. It will also develop GMPc sources for manufacturing. Telik will have the option to re-acquire C243 rights in the future.
In North and South America, Telik has exclusive commercialization rights to C243. Sanwa Kagaku Kenkyusho and Telik share commercialization rights to the compound in Europe, and Sanwa has exclusive commercialization rights in Asia. The license agreement covers territories where Telik has exclusive rights.